乳腺监视钼靶阴性后 interval 浸润性第二乳腺癌的累积风险分布
基于乳腺癌监测联盟 18,366 例单侧 DCIS 或 I–III 期浸润性乳腺癌患者 1996–2012 年的 65,084 次监视钼靶,评估钼靶阴性后 1 年内 interval 浸润性第二乳腺癌风险。interval 浸润癌率为 2.9/1,000 次检查,5 年累积风险中位 1.4%,15% 女性≥3%。
要点
- interval 浸润癌率 2.9/1,000 次检查,5 年累积风险中位 1.4%。
- 15% 女性 5 年 interval 浸润癌风险≥3%。
- ER 和 PR 阴性原发癌者风险最高,5 年累积 2.6%。
核心结论
- interval 浸润性第二乳腺癌风险因患者特征而异,受初诊、治疗和影像特征影响。
- 应开发评估监视钼靶未检出癌风险的预测模型,以支持个体化监视讨论。
研究设计与样本
- 回顾性队列研究,纳入乳腺癌监测联盟 18,366 例单侧 DCIS 或 I–III 期浸润性乳腺癌女性。
- 分析 1996–2012 年 65,084 次监视钼靶,采用离散时间生存模型估计 5 年累积 interval 浸润癌概率。
主要发现
- 监视检出癌 474 例(334 例浸润性、140 例 DCIS),interval 浸润癌 186 例。
- 癌检出率 7.3/1,000 次检查(95%CI 6.6–8.0),interval 浸润癌率 2.9/1,000 次检查(95%CI 2.5–3.3)。
- 5 年 interval 癌累积风险中位 1.4%(IQR 0.8%–2.3%;10th–90th 百分位 0.5%–3.7%),15% 女性≥3%。
- ER 和 PR 阴性原发癌者 5 年累积风险 2.6%(95%CI 1.7%–3.5%)。
- 初诊即为 interval 癌表现者 2.2%(95%CI 1.5%–2.9%),保乳未放疗者 1.8%(95%CI 1.1%–2.4%)。
临床怎么用
- 可利用初诊、治疗和影像特征识别 interval 浸润癌高危女性,个体化讨论监视策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The aim of the current study was to characterize the risk of interval invasive second breast cancers within 5 years of primary breast cancer treatment. Methods We examined 65,084 surveillance mammograms from 18,366 women with a primary breast cancer diagnosis of unilateral ductal carcinoma in situ or stage I to III invasive breast carcinoma performed from 1996 to 2012 in the Breast Cancer Surveillance Consortium. Interval invasive breast cancer was defined as ipsilateral or contralateral cancer diagnosed within 1 year after a negative surveillance mammogram. Discrete-time survival models-adjusted for all covariates-were used to estimate the probability of interval invasive cancer, given the risk factors for each surveillance round, and aggregated across rounds to estimate the 5-year cumulative probability of interval invasive cancer. Results We observed 474 surveillance-detected cancers-334 invasive and 140 ductal carcinoma in situ-and 186 interval invasive cancers which yielded a cancer detection rate of 7.3 per 1,000 examinations (95% CI, 6.6 to 8.0) and an interval invasive cancer rate of 2.9 per 1,000 examinations (95% CI, 2.5 to 3.3). Median cumulative 5-year interval cancer risk was 1.4% (interquartile range, 0.8% to 2.3%; 10th to 90th percentile range, 0.5% to 3.7%), and 15% of women had ≥ 3% 5-year interval invasive cancer risk. Cumulative 5-year interval cancer risk was highest for women with estrogen receptor- and progesterone receptor-negative primary breast cancer (2.6%; 95% CI, 1.7% to 3.5%), interval cancer presentation at primary diagnosis (2.2%; 95% CI, 1.5% to 2.9%), and breast conservation without radiation (1.8%; 95% CI, 1.1% to 2.4%). Conclusion Risk of interval invasive second breast cancer varies across women and is influenced by characteristics that can be measured at initial diagnosis, treatment, and imaging. Risk prediction models that evaluate the risk of cancers not detected by surveillance mammography should be developed to inform discussions of tailored surveillance.
引用
- Lee JM, Abraham L, Lam DL, et al. Cumulative Risk Distribution for Interval Invasive Second Breast Cancers After Negative Surveillance Mammography. J Clin Oncol. 2018. PMID: 29718790. doi:10.1200/JCO.2017.76.8267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。